Medication compliance as a feature in drug development

Annual Review of Pharmacology and Toxicology

Volumn 37, Issue , 1997, Pages 451-475

  Kastrissios, H ^a   Blaschke, T F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trials; patient compliance

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; CALCIUM ANTAGONIST; HORMONE;

CLINICAL TRIAL; COST; DRUG DEVELOPMENT; DRUG DOSE; DRUG MONITORING; HUMAN; PATIENT COMPLIANCE; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; INFORMED CONSENT; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; TREATMENT REFUSAL;

EID: 0031011748     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (92)

1. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, et al. 1992. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:465-73
2. Jones WHS. 1923. On decorum. In Hippocrates, ed. TE Page, E Capps, WHD Rouse, LA Post, EH Warmington, 2:269-301. London: Heinemann
3. Sackett DL, Haynes RB. 1976. Compliance with Therapeutic Regimens. Baltimore: Johns Hopkins Univ. Press
4. Haynes RB, Taylor DW, Sackett DL, eds. 1979. Compliance in Health Care. Baltimore: Johns Hopkins Univ. Press
5. Vander Stichele R. 1991. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur. J. Clin. Pharmacol. 41:27-35
6. Efron B, Feldman D. 1991. Compliance as an explanatory variable in clinical trials. J. Am. Stat. Assoc. 86:9-17
7. Meier P. 1991. Comment. J. Am. Stat. Assoc. 86:19-22
8. Rubin DB. 1991. Comment: dose-response estimands. J. Am. Stat. Assoc. 86:22-24
9. Zeger SL, Liang K-Y. 1991. Comment: dose-response estimands. J. Am. Stat. Assoc. 86:18-19
10. Efron B, Feldman D. 1991. Rejoinder: compliance as an explanatory variable in clinical trials. J. Am. Stat. Assoc. 86:25-26
11. Cramer JA, Spilker B, eds 1991. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven
12. Kapur S, Ganguli R, Ulrich R, Raghu U. 1992. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophrenia Res. 6:49-53
13. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. 1986. Compliance with topical pilocarpine treatment. Am. J. Ophthal. 101:515-23
14. Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. 1993. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur. J. Clin. Pharmacol. 45:211-15
15. Nides MA, Tashkin DP, Simmons MS, Wise RA, Li VC, Rand CS. 1993. Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. Chest 104:501-7
16. Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne DJ, et al. 1991. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am. J. Med. 91:462-70
17. Petri H, Urquhart J. 1994. Patient compliance with beta-blocker medication in general practice. Pharmacoepid Drug Safety 3:251-56
18. Rodewald LE, Pichichero ME. 1993. Compliance with antibiotic therapy: a comparison of deuterium oxide tracer, urine bioassay, bottle weights, and parental reports. J. Pediatr. 123:143-47
19. Rudd P, Ramesh J, Bryant-Kosling C, Guerrero D. 1993. Gaps in cardiovascular medication taking: the tip of the iceberg. J. Gen. Intern. Med. 8:659-66
20. Waterhouse DM, Calzone KA, Mele C, Brenner DE. 1993. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J. Clin. Oncol. 11:1189-97
21. Haynes RB. 1979. Introduction. See Ref. 4, pp. 1-7
22. Kruse W. 1992. Patient compliance with drug treatment - new perspectives on an old problem. Clin. Investig. 70:163-66
23. Kastrissios H, Suarez JR, Girard P, Sheiner LB, Blaschke TF. 1996. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. In preparation
24. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. 1990. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin. Pharmacol. Ther. 48:676-85
25. Urquhart J. 1996. How much compliance is enough? Pharm. Res. 13:10-11
26. Potter LS. 1991. Oral contraceptive compliance and its role in the effectiveness of the method. See Ref. 11, pp. 195-207
27. Cheung R, Sullens CM, Seal D, Dickins J, Nicholson PW, et al. 1988. The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community. Br. J. Clin. Pharmac. 26:391-98
28. Kastrissios H, Flowers NT, Blaschke TF. 1996. Introducing medical students to medication noncompliance. Clin. Pharmacol. Ther. 59:577-82
29. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G. 1994. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J. Clin. Pharmacol. 34:944-49
30. Maronde RF, Chan LS, Larsen FJ, Strandberg LR, Laventurier MF, Sullivan SR. 1989. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 27:1159-66
31. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. 1990. Non-compliance in organ transplant recipients. Transplantation 49:374-77
32. Browman GP, Arnold A, Booker L, Johnstone B, Skingley P, Levine MN. 1989. Etretinate blood levels in monitoring of compliance and contamination in chemoprevention trial. J. Natl Cancer Inst. 81:795-98
33. Friedman IM, Litt IF, King DR, Henson R, Holtzman D, et al. 1986. Compliance with anticonvulsant therapy by epileptic youth. J. Adolesc. Health Care 7:12-17
34. Leppik IE, Cloyd JC, Sawchuk RJ, Pepin SM. 1979. Compliance and variability of plasma phenytoin levels in epileptic patients. Ther. Drug Monit. 1:475-83
35. Turgeon DK, Leichtman AB, Blake DS, Schmouder RL, Lown KS, et al. 1994. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. Transplantation 51:1136-41
36. Nakano M, Uematsu T, Sato H, Kosuge K, Nishimoto M, Nakashima M. 1994. Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol. Eur. J. Clin. Pharmacol. 47:195-202
37. Lim L-Y. 1992. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 48:619-30
38. Cramer JA, Scheyer RD, Mattson R. 1990. Compliance declines between clinic visits. Arch. Intern. Med. 150:1509-10
39. Feely M, Cooke J, Price D, Singleton S, Mehta A, et al. 1987. Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br. J. Clin. Pharmac. 24:77-83
40. Mäenpää H, Heinonen OP, Manninen V. 1991. Medication compliance and serum lipid changes in the Helsinki Heart Study. Br. J. Clin. Pharmac. 32:409-15
41. Young LM, Haakenson CM, Lee KK, van Eeckhout JP. 1984. Riboflavin use as a drug marker in Veterans Administration Cooperative Studies. Cant. Clin. Trials 5:497-504
42. Kim HM, Lagakos SW. 1994. Assessing drug compliance using longitudinal marker data, with application to AIDS. Stat. Med. 13:2141-53
43. Lassen JF, Brandslund I, Antonsen S. 1995. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin. Chem, 41:444-47
44. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. 1995. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 274:945-51
45. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC. 1994. Implications of directly observed therapy in tuberculosis control measures among IDUs. Pub. Health Rep. 109:319-27
46. Sackett DL. 1979. Methods for compliance research. See Ref. 4, pp. 321-33
47. Pullar T, Kumar S, Chrystyn H, Rice P, Peaker S, Feely MP. 1991. The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. Br. J. Clin. Pharmac. 32:329-33
48. Detry J-M R, Block P, De Backer G, Degaute J-P, Six R. 1994. Patient compliance and therapeutic coverage: amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris. J. Int. Med. Res. 22:278-86
49. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. 1990. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150:1881-84
50. Kruse W, Weber E. 1990. Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring. Eur. J. Clin. Pharmacol. 38:561-65
51. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. 1991. Dosage frequency and drug-compliance behaviour -a comparative study on compliance with a medication to be taken twice or four times daily. Eur. J. Clin. Pharmacol. 41:589-92
52. Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. 1993. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J. Hypertens. 11:1403-11
53. Steiner TJ, Catarci T, Hering R, Whitmarsh T, Couturier EGM. 1994. If migraine prophylaxis does not work, think about compliance. Cephalalgia 14:463-64
54. Urquhart J. 1992. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad. Med. J. 68:S49-S59
55. Weidler D, Wallin JD, Cook E, Dillard D, Lewin A. 1992. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. J. Clin. Pharmacol. 32:444-49
56. Girard P, Sheiner L, Kastrissios H, Blaschke T. 1996. A markov model for drug compliance with application to HIV+ patients. Clin. Pharmacol. Ther. 59:157
57. Cramer JA, Mattson RH. 1991. Monitoring compliance with antiepileptic drug therapy. See Ref. 11, pp. 123-37
58. Cramer JA, Ouellette VL, Mattson RH. 1990. Effect of microelectronic observation on compliance. Epilepsia 31:617-18
59. Levy G. 1993. A pharmacokinetic perspective on medicament noncompliance. Clin. Pharmacol Ther. 54:242-44
60. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. 1996. Do we need full compliance data for population pharmacokinetic analysis? J. Pharmacokin. Biopharm. In press
61. Rubio A, Cox C, Weintraub M. 1992. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin. Pharmacokinet. 22:238-46
62. Johnson BF, Whelton A. 1994. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am. J. Ther. 1:260-67
63. Sambol NC, Sheiner LB. 1991. Population dose versus response of betaxolol and atenolol: a comparison of potency and variability. Clin. Pharmacol. Ther. 49:24-31
64. Iseman MD, Madsen LA. 1989. Drug-resistant tuberculosis. Clin. Chest Med. 10:341-54
65. Bloom BR, Murray CJL. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:1055-64
66. Vanhove GF, Schapiro JM, Winters MM, Merigan TC, Blaschke TF. 1996. Compliance and drug failure in protease inhibitor monotherapy. JAMA. In press
67. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. 1994. The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers. JAMA 263:1653-57
68. Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, et al. 1989. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb. Haemostasis 62:729-32
69. Van Den Besselaar AMHP, Van Der Meer FJM, Gerrits-Drabbe CW. 1988. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am. J. Clin. Pathol. 90:685-90
70. Briggs WA, Lowenthal DT, Cirksena WJ, Price WE, Gibson TP, Flamenbaum W. 1975. Propranolol in hypertensive dialysis patients: efficacy and compliance. Clin. Pharmacol. Ther. 18:606-12
71. Frank E, Perel JM, Mallinger AG, Thase ME, Kupfer DJ. 1992. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol. Bull. 28:231-35
72. Hasford J. 1991. Analyzing partial compliance in clinical trials. See Ref. 11, pp. 265-81
73. Sheiner LB, Rubin DB. 1995. Intention-to-treat analysis and the goals of clinical trials. Clin. Pharmacol Ther. 57:6-15
74. Goetghebeur EJT, Pocock SJ. 1993. Statistical issues in allowing for noncompliance and withdrawal. Drug Inform. J. 27:837-45
75. Urquhart J. 1991. Patient compliance as an explanatory variable in four selected cardiovascular studies. See Ref. 11, pp. 301-22
76. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. 1993. Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Clin. Investig. 71:483-87
77. Schechtman KB, Gordon MO. 1994. The effect of poor compliance and treatment side effects on sample size requirements in randomized clinical trials. J. Biopharmaceut. Stat. 4:223-32
78. Freedman LS. 1990. The effect of partial noncompliance on the power of a clinical trail. Cont. Clin. Trials 11:157-68
79. Moussa MAA. 1990. Planning the size of a clinical trial with allowance for patient noncompliance. Meth. Inform. Med. 29:243-46
80. Lang JM. 1990. The use of a run-in to enhance compliance. Stat. Med. 9:87-95
81. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. 1991. Analysis of clinical trials by treatment actually received: Is it really an option? Stat. Med. 10:1595-605
82. Peck CC. 1996. Testimony to Congress. Streamlining and modernizing drug development. Subcommittee on Health and Environment, Committee on Commerce, United States House of Representatives
83. Rosenberg MJ, Waugh MS. 1996. The economics of compliance in managed healthcare settings. Am. J. Man. Care 2:176-80
84. Weiden PJ, Olfson M. 1995. Cost of relapse in schizophrenia. Schizophrenia Bull. 21:419-29
85. Cheung R, Dickins J, Nicholson PW, Thomas ASC, Smith HH, et al. 1988. Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed electronic recording device. Eur. J. Clin. Pharmacol. 35:401-7
86. Kruse W, Koch-Gwinner P, Nikolaus T, Oster P, Schlierf G, Weber E. 1992. Measurement of drug compliance by continuous electronic monitoring: a pilot study in elderly patients discharged from hospital. J. Am. Geriatr. Soc. 40:1151-55
87. Metry J-M R, Block P, De Backer G, Degaute J-P, Six R. 1995. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur. J. Clin. Pharmacol. 47:477-81
88. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. 1992. Issues in patient compliance: the search for therapeutic sufficiency. Cardiology 80:2-10
89. Gordon ME, Kass MA. 1991. Validity of standard compliance measures in glaucoma compared with an electronic eyedrop monitor. See Ref. 11, pp. 163-73
90. Mawhinney H, Spector SL, Kinsman RA, Siegel S, Rachelefsky GS, et al. 1991. Compliance in clinical trials of two non-bronchodilator, antiasthma medications. Ann. Allergy 66:294-99
91. Farmer KC, Jacobs EW, Phillips CR. 1994. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin. Ther. 16:316-26
92. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. 1990. Compliance with short-term high-dose ethinyl oestradiol in young patients with primary infertility. Agents Actions 29:105-15